Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Forms $270 Million Partnership with GHDDI for COVID-19 Therapy

publication date: Aug 23, 2022

Shanghai Hansoh Pharma will partner with Beijing’s Global Health Drug Development Center to develop and commercialize the Center’s novel COVID-19 therapy. GDI-4405 is a pre-clinical oral candidate that targets the coronavirus 3CL protease. In pre-clinical tests, GDI-4405 has shown potent inhibition of SARS-CoV-2 replication with good bioavailability and safety. Hansoh will make a $2 million upfront payment, and it will be responsible for up to $268 million in milestones, plus royalties on sales. Formed in 2016, GHDDC is a non-profit organization formed by the Gates Foundation, Tsinghua University and the Beijing Municipal Government. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital